News | Radiation Therapy | October 22, 2015

Pediatric Ependymoma Patients Have Favorable Outcomes With Immediate Post-surgical Radiation Therapy

Large Children’s Oncology Group trial reports five-year event free survival

pediatric ependymoma patients, immediate post-surgical radiation therapy, Children's Oncology Group ACNS0121 trial, ASTRO 2015

October 22, 2015 — Outcomes for pediatric patients as young as 12 months with ependymoma who are treated with immediate post-operative radiation therapy are favorable and consistent based upon the patients’ tumor surgical resection and tumor grade, according to new research. Findings from the study were presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.  

The Children’s Oncology Group ACNS0121 trial was a prospective study for childhood ependymoma (EP)— a rare type of brain and spinal cord tumor that arises from the ependyma, a tissue of the central nervous system. This was the largest prospective trial for childhood ependymoma ever conducted, and the first cooperative group trial for ependymoma to target the post-operative tumor bed and to use three-dimensional conformal radiation therapy (3-D CRT) and intensity-modulated radiation therapy (IMRT). In addition, this study is significant in that it was the first to systematically use immediate post-operative radiation therapy in children under the age of three with this type of brain tumor. Many children diagnosed with ependymoma are younger than three years old. Prior studies did not include the use of radiation therapy in frontline management for very young children with ependymoma.

The study was conducted from 2003 to 2007 to determine the rate of tumor control in children with ependymoma who were treated with conformal radiation therapy using a 1cm clinical target volume margin surrounding the post-operative tumor bed. The underlying goals were to reduce the volume of radiation therapy and decrease the risk of side effects without affecting the rate of tumor control.

The trial included 378 patients from 115 institutions. The average patient age was 5.3 years (range 1.01-21.01 years), and each patient had been newly diagnosed. There were 216 patients with World Health Organization (WHO) grade II tumors and 140 with WHO grade III tumors. Patients were enrolled in the study within 56 days of initial surgical resection (removal of part or all of the tumor).

Researchers categorized the patients into non-overlapping subgroups or stratums. The study was designed to: observe patients with WHO grade II supratentorial ependymoma (tumors in the upper part of the brain) after microscopically complete (GTR1) surgical resection (stratum 1); administer chemotherapy with optional second surgery prior to CRT for patients with subtotal (STR) resection at the time of protocol enrollment (stratum 2); and administer immediate post-operative CRT for patients with either near-total (NTR defined as < 5mm residual thickness) or macroscopic gross-total (GTR2) resection (stratum 3) or with WHO grade III, supratentorial or any infratentorial ependymoma (tumors in or around the fourth ventricle) after GTR1 (stratum 4).

Stratum 2 patients were treated with pre-CRT chemotherapy consisting of two three-week cycles of vincristine, carboplatin and cyclophosphamide (cycle 1) and etoposide (cycle 2); and some of the stratum 2 patients had a second surgery prior to CRT. Stratum 3 and stratum 4 patients received post-operative CRT. Radiation was administered using a 1 cm clinical target volume margin. The cumulative total dose was 59.4 Gy, except for patients younger than 18 months after GTR.

One endpoint the study measured to evaluate the effectiveness of treatment was the rate of patients’ five-year event free survival (EFS). In cancer, EFS refers to a length of time after primary treatment that the patient remains free of certain complications or events (such as the return of the cancer or onset of symptoms) that the treatment was intended to prevent or delay.

Data indicated that progression (meaning the cancer was spreading or getting worse) was observed in five of the 11 eligible stratum 1 patients, and the five-year EFS rate for patients in stratum 1 was 61.4 percent + 14.4 percent. In stratum 2, a second surgery was performed in 25 of the 64 patients, and GTR was achieved in 14 patients. There was no difference in EFS comparing the 25 patients that underwent a second surgery to the 39 patients that did not (log-rank test: P=0.0790). The EFS rate for stratum 2 patients was 39.2 percent + 7 percent. The EFS rate for patients in stratum 3 was 67.3 percent + 4.5 percent; and 69.5 percent + 3.8 percent for patients in stratum 4. Among the 281 patients treated on stratum 3 and 4, EFS was 74.6 + 3.6 percent for those with WHO grade II tumors and 60.7 percent + 4.7 percent for those with WHO grade III tumors, according to central pathology review (log-rank test: P=0.0047).

“These results indicate that radiation therapy may be safely administered to children of all ages with ependymoma and high rate of tumor control may be achieved for the majority of children,” said Thomas E. Merchant, DO, Ph.D., lead author of the study and Baddia J. Rashid Endowed Chair in Radiation Oncology at St. Jude Children's Research Hospital. “All children with ependymoma should receive expert care and treatment teams should follow protocol guidelines similar to those used in this study with consideration given to the importance of gross total tumor resection and advances in radiation therapy methods. Other treatments, in addition to surgery and radiation therapy, should be investigated to further increase the rate of tumor control.”

For more information: www.astro.org

Related Content

Philips Launches IntelliSpace Discovery Research Platform at RSNA
Technology | Artificial Intelligence | November 20, 2018
Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Royal Philips...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...